STOCK TITAN
  1. Home
  2. News
  3. HCM

HUTCHMED (China) Limited American Depositary Shares - HCM STOCK NEWS

Welcome to our dedicated page for HUTCHMED (China) American Depositary Shares news (Ticker: HCM), a resource for investors and traders seeking the latest updates and insights on HUTCHMED (China) American Depositary Shares stock.

HUTCHMED China Ltd, formerly known as Hutchison China Meditech Ltd, is a prominent player in the healthcare sector, focusing primarily on the manufacturing and sale of pharmaceuticals. The company is engaged in the development, production, and commercialization of therapies targeting oncology and immunological diseases. HUTCHMED operates through three main business segments: Innovation Platform, Commercial Platform, and Production.

Within the Innovation Platform, HUTCHMED dedicates extensive resources to research and development, aiming to discover novel drug candidates and advance them through clinical trials. The Commercial Platform includes the marketing and distribution aspects, where the company leverages its significant presence in China to bring its products to market. The Production segment focuses on the manufacturing of these drugs, following stringent quality standards.

HUTCHMED has achieved several milestones, including the development of its flagship products such as Savolitinib and Sulfatinib, which are undergoing various stages of clinical trials. Recent updates indicate promising subgroup efficacy and improved quality of life data, as presented at ASCO 2024. These advancements underline the company's commitment to addressing unmet medical needs and enhancing patient care.

Financially, HUTCHMED maintains a robust pipeline of projects and collaborations with global pharmaceutical giants, bolstering its position in the market. The company's strategic partnerships and alliances play a crucial role in expanding its research capabilities and accelerating drug development processes.

Overall, HUTCHMED China Ltd stands as a noteworthy entity in the pharmaceutical industry, continually striving to innovate and improve its product offerings to meet the growing healthcare demands in China and beyond.

News

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Rhea-AI Summary
HUTCHMED and Innovent Biologics announce NDA acceptance and Priority Review for fruquintinib and sintilimab combination therapy for advanced endometrial cancer. The NDA is supported by data from FRUSICA-1 Phase II study, showing promising results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
News

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Rhea-AI Summary
HUTCHMED (HCM) announces Phase IIIb data for savolitinib in NSCLC, showing promising results with median PFS of 13.7 months and expanded indication for treatment-naïve patients in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
News

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Rhea-AI Summary
HUTCHMED initiates Phase II/III clinical trial for sovleplenib in wAIHA patients in China, following positive Phase II data. The trial aims to confirm safety and efficacy, with the first patient dosed on March 20, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
clinical trial
News

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

Rhea-AI Summary
HUTCHMED Reports 97% Revenue Growth to $838M, FDA Approval, and NDA Review for Sovleplenib
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.88%
Tags
none
-
News

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

Rhea-AI Summary
HUTCHMED (China) Limited announces positive results from the Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China. The trial showed a statistically significant improvement in progression-free survival and overall response rate, as well as other endpoints. The safety profile was consistent with expectations, and the combination therapy could be a promising second-line treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
clinical trial
-
News

Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED

Rhea-AI Summary
Inmagene Biopharmaceuticals exercised its option to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor. Inmagene retains rights to develop and commercialize both assets worldwide. The collaboration with HUTCHMED has allowed Inmagene to take these assets from pre-clinical to clinical development. IMG-007 is being evaluated in Phase 2a studies in two indications, while IMG-004 is being evaluated in a Phase 1 multiple ascending dose (MAD) study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
none
News

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

Rhea-AI Summary
HUTCHMED announced that Inmagene Biopharmaceuticals has exercised options to license two drug candidates discovered by HUTCHMED, IMG-007 and IMG-004, pursuant to a strategic partnership. Inmagene will be granted an exclusive license to further develop, manufacture, and commercialize these two drug candidates worldwide. HUTCHMED is entitled to receive potential payments of up to US$92.5 million for development milestones and up to US$135 million for commercial milestones, as well as royalties upon commercialization. In 2023, Inmagene initiated two global Phase IIa clinical trials for IMG-007 and completed a Phase I study for IMG-004. Dr. Weiguo Su, CEO of HUTCHMED, highlighted the progress and potential impact of the partnership on developing innovative drug candidates for patients with immunological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
partnership
-
News

HUTCHMED to Announce 2023 Final Results

Rhea-AI Summary
HUTCHMED (China) Limited will be announcing its final results for the year ended December 31, 2023 on February 28, 2024. Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will take place at 7:30 am EST on February 28, 2024, and there will also be a Chinese webcast on February 29, 2024. Both webcasts will be available live via the company website at www.hutch-med.com/event/
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
none
-
News

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

Rhea-AI Summary
HUTCHMED (China) Limited announces the marketing approval of ELUNATE® (fruquintinib) by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer. This marks the first medicine to be approved under the new '1+' mechanism by the HKSAR Government, allowing drugs beneficial for life-threatening diseases to apply for registration with supporting local clinical data and recognition from relevant experts. ELUNATE® is a selective oral inhibitor of VEGF receptors -1, -2, and -3, and is the first oral targeted therapy approved in Hong Kong for metastatic colorectal cancer in almost a decade. Fruquintinib has already been approved in mainland China, Macau SAR, and the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
none
News

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Rhea-AI Summary
HUTCHMED (China) Limited (HCM) announces that the New Drug Application (NDA) for sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (ITP) has been accepted for review and granted priority review by the China National Medical Products Administration (NMPA). Sovleplenib is a novel, selective, oral inhibitor targeting spleen tyrosine kinase (Syk), being developed for the treatment of hematological malignancies and immune diseases. The NDA is supported by data from ESLIM-01, a randomized, double-blinded, placebo-controlled Phase III trial in China of sovleplenib in 188 adult patients with primary ITP who have received at least one prior line of standard therapy. In August 2023, the trial had met its primary endpoint of demonstrating a clinically meaningful and a statistically significant increase in durable response rate in patients treated with sovleplenib as compared to patients treated with placebo. Secondary endpoints including response rate and safety were also met. The NMPA granted Breakthrough Therapy designation (BTD) to sovleplenib for the indication studied in ESLIM-01 in January 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
none

FAQ

What is the current stock price of HUTCHMED (China) American Depositary Shares (HCM)?

The current stock price of HUTCHMED (China) American Depositary Shares (HCM) is $14.31 as of December 20, 2024.

What is the market cap of HUTCHMED (China) American Depositary Shares (HCM)?

The market cap of HUTCHMED (China) American Depositary Shares (HCM) is approximately 2.5B.

What does HUTCHMED China Ltd specialize in?

HUTCHMED China Ltd specializes in the development, production, and sale of pharmaceuticals, particularly targeting oncology and immunological diseases.

What are the key business segments of HUTCHMED?

HUTCHMED operates through three main business segments: Innovation Platform, Commercial Platform, and Production.

What are some of HUTCHMED's flagship products?

HUTCHMED's flagship products include Savolitinib and Sulfatinib, currently in various stages of clinical trials.

How does HUTCHMED contribute to the healthcare sector?

HUTCHMED contributes by developing innovative therapies for oncology and immunological diseases, enhancing patient care and addressing unmet medical needs.

What recent achievements has HUTCHMED made?

HUTCHMED recently presented promising subgroup efficacy and quality of life data at ASCO 2024.

What financial position does HUTCHMED hold?

HUTCHMED maintains a robust pipeline and collaborates with global pharmaceutical giants, strengthening its market position.

Who are HUTCHMED's partners?

HUTCHMED collaborates with several global pharmaceutical companies to enhance its research and development capabilities.

What is the focus of HUTCHMED's Innovation Platform?

The Innovation Platform focuses on discovering new drug candidates and advancing them through clinical trials.

How does HUTCHMED's Commercial Platform function?

The Commercial Platform involves the marketing and distribution of HUTCHMED's pharmaceutical products, primarily in China.

What standards does HUTCHMED's Production segment follow?

HUTCHMED's Production segment adheres to stringent quality standards to ensure the efficacy and safety of its drugs.

Stock HCM logo
HUTCHMED (China) Limited American Depositary Shares

Nasdaq:HCM

HCM Rankings

#1810 Ranked by Market Cap
N/A Ranked by Dividends

HCM Stock Data

2.48B
174.10M
0.13%
4.29%
0.31%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Hong Kong